Eli Lily commences trial for COVID-19 antibody treatment

Eli Lilly has recently begun dosing patients in the world’s first trial for treatment designed to attack SARS-CoV-2, the virus that causes COVID-19. This investigational treatment, referred to as LY-CoV555, is the first produced as a result of the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Scientists developed

Continue Reading

New UK trial looks to reduce COVID-19 drug development to a few weeks

The new UK trial initiative aims to cut the design phase of clinical studies for potential COVID-19 drugs from around 18 months to a few weeks. The ACCORD-2 collaboration will examine the effectiveness of repurposed medicines, potential new drugs, and currently unlicensed therapies in treating COVID-19 patients. Drug compounds that demonstrate effectiveness and safety in the early clinical trials stage

Continue Reading

“Safety does not come with luck. It must be prepared” – Pharmacovigilance Report

Our latest industry analytics report features analysis on the drug safety sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “The global pharmacovigilance (PV) market size was estimated at $4.87 billion in 2019, according to a Global Market Insights report, by 2024 the market is predicted to exceed US$8 billion .

Continue Reading

Karyopharm announce Xpovio meets endpoints in Phase III trial

The pharmaceutical company announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor). The drug in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) met its primary endpoint of a statistically significant increase in progression-free survival (PFS) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd). The trial saw the

Continue Reading